Complicated Reason 1 O O
Long Reason 1 O O
Term Reason 1 O O
Vaccine Reason 1 O O
Induced Reason 1 O O
Thrombotic Reason 1 O O
Immune Reason 1 O O
Thrombocytopenia-A Reason 1 O O
Case Reason 1 O O
Report Reason 1 O O
- Reason 1 O O
PMID: Reason 1 O O
34835275 Reason 1 O O
- Reason 1 O O
PMCID: Reason 1 O O
- Reason 1 O O
- Reason 1 O O
[10.3390/vaccines9111344](https://doi.org/10.3390/vaccines9111344) O O O O
Complicated O O O O
Long O O O O
Term O O O O
Vaccine O O O O
Induced O O O O
Thrombotic O O O O
Immune O O O O
Thrombocytopenia-A O O O O
Case O O O O
Report O O O O
Abstract O O O O
Background O O O O
and O O O O
objectives: O O O O
Vaccine O O O O
induced O O O O
thrombotic O O O O
thrombocytopenia O O O O
(VITT) O O O O
may O O O O
occur O O O O
after O O O O
COVID-19 O O O O
vaccination O O O O
with O O O O
recombinant O O O O
adenoviral O O O O
vector-based O O O O
vaccines. O O O O
VITT O O O O
can O O O O
present O O O O
as O O O O
cerebral O O O O
sinus O O O O
and O O O O
venous O O O O
thrombosis O O O O
(CSVT), O O O O
often O O O O
complicated O O O O
by O O O O
intracranial O O O O
hemorrhage. O O O O
Today O O O O
it O O O O
is O O O O
unclear, O O O O
how O O O O
long O O O O
symptomatic O O O O
VITT O O O O
can O O O O
persist. O O O O
Here, O O O O
we O O O O
report O O O O
the O O O O
complicated O O O O
long-term O O O O
course O O O O
of O O O O
a O O O O
VITT O O O O
patient O O O O
with O O O O
extremely O O O O
high O O O O
titers O O O O
of O O O O
pathogenic O O O O
anti-platelet O O O O
factor O O O O
4 O O O O
(PF4)-IgG O O O O
antibodies. O O O O
Methods: O O O O
Clinical O O O O
and O O O O
laboratory O O O O
findings O O O O
are O O O O
presented, O O O O
including O O O O
the O O O O
course O O O O
of O O O O
platelet O O O O
counts, O O O O
D-Dimer O O O O
levels, O O O O
clinical O O O O
presentation, O O O O
imaging, O O O O
SARS-CoV-2-serological O O O O
and O O O O
immunological, O O O O
platelet O O O O
activating O O O O
anti-PF4-IgG, O O O O
as O O O O
well O O O O
as O O O O
autopsy O O O O
findings. O O O O
Results: O O O O
The O O O O
patient O O O O
presented O O O O
with O O O O
extended O O O O
superior O O O O
sagittal O O O O
sinus O O O O
thrombosis O O O O
with O O O O
accompanying O O O O
bifrontal O O O O
intracerebral O O O O
hemorrhage. O O O O
Repeated O O O O
treatment O O O O
intravenous O O O O
immune O O O O
globuline O O O O
recurrent O O O O
episodes O O O O
of O O O O
thrombocytopenia. O O O O
Moreover, O O O O
the O O O O
patient's O O O O
serum O O O O
remained O O O O
strongly O O O O
positive O O O O
for O O O O
platelet-activating O O O O
anti-PF4-IgG O O O O
over O O O O
three O O O O
months. O O O O
After O O O O
a O O O O
period O O O O
of O O O O
clinical O O O O
stabilization, O O O O
the O O O O
patient O O O O
suffered O O O O
a O O O O
recurrent O O O O
and O O O O
fatal O O O O
intracranial O O O O
hemorrhage. O O O O
Conclusions: O O O O
Complicated O O O O
VITT O O O O
with O O O O
extremely O O O O
high O O O O
anti-PF4-IgG O O O O
titers O O O O
over O O O O
three O O O O
months O O O O
can O O O O
induce O O O O
recurrent O O O O
thrombocytopenia O O O O
despite O O O O
treatment O O O O
with O O O O
IVIG O O O O
and O O O O
anticoagulation. O O O O
Plasma O O O O
exchange, O O O O
immunoadsorption, O O O O
and O O O O
/or O O O O
immunosuppressive O O O O
treatment O O O O
may O O O O
be O O O O
considered O O O O
in O O O O
complicated O O O O
VITT O O O O
to O O O O
reduce O O O O
extraordinarily O O O O
high O O O O
levels O O O O
of O O O O
anti-PF4-IgG. O O O O
Long-term O O O O
therapy O O O O
in O O O O
such O O O O
cases O O O O
must O O O O
take O O O O
the O O O O
individual O O O O
bleeding O O O O
risk O O O O
and O O O O
CSVT O O O O
risk O O O O
into O O O O
account. O O O O
Keywords: O O O O
COVID-19; O O O O
autoimmune; O O O O
case O O O O
report; O O O O
cerebral O O O O
statement O O O O
Günther Reason 3 O O
reports Reason 3 O O
speakers' Reason 3 O O
honoraria Reason 3 O O
from Reason 3 O O
Bayer Reason 3 O O
Vital Reason 3 O O
GmbH, Reason 3 O O
Bristol Reason 3 O O
Myers Reason 3 O O
Squibb, Reason 3 O O
Daichii Reason 3 O O
Sankyo, Reason 3 O O
and Reason 3 O O
research Reason 3 O O
grant Reason 3 O O
from Reason 3 O O
IPSEN Reason 3 O O
outside Reason 3 O O
the Reason 3 O O
submitted Reason 3 O O
work. Reason 3 O O
Thiele Reason 3 O O
reports Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
and Reason 3 O O
other Reason 3 O O
from Reason 3 O O
Bristol Reason 3 O O
Myers Reason 3 O O
Squibb, Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
and Reason 3 O O
other Reason 3 O O
from Reason 3 O O
Pfizer, Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
from Reason 3 O O
Bayer, Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
and Reason 3 O O
other Reason 3 O O
from Reason 3 O O
Chugai Reason 3 O O
Pharma, Reason 3 O O
other Reason 3 O O
from Reason 3 O O
Novo Reason 3 O O
Nordisk, Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
from Reason 3 O O
Novartis, Reason 3 O O
other Reason 3 O O
from Reason 3 O O
Daichii Reason 3 O O
Sankyo, Reason 3 O O
outside Reason 3 O O
the Reason 3 O O
submitted Reason 3 O O
work. Reason 3 O O
Greinacher Reason 3 O O
reports Reason 3 O O
grants Reason 3 O O
and Reason 3 O O
non-financial Reason 3 O O
support Reason 3 O O
from Reason 3 O O
Aspen, Reason 3 O O
Boehringer Reason 3 O O
Ingelheim, Reason 3 O O
Bristol Reason 3 O O
Myers Reason 3 O O
Squibb, Reason 3 O O
Paringenix, Reason 3 O O
Bayer Reason 3 O O
Healthcare, Reason 3 O O
Gore Reason 3 O O
Inc., Reason 3 O O
Rovi, Reason 3 O O
Sagent, Reason 3 O O
Biomarin/Prosensa, Reason 3 O O
personal Reason 3 O O
fees Reason 3 O O
from Reason 3 O O
Aspen, Reason 3 O O
Boehringer Reason 3 O O
Ingelheim, Reason 3 O O
Macopharma, Reason 3 O O
Chromatec, Reason 3 O O
Instrumentation Reason 3 O O
Laboratory, Reason 3 O O
non-financial Reason 3 O O
support Reason 3 O O
from Reason 3 O O
Boehringer Reason 3 O O
Ingelheim, Reason 3 O O
Portola, Reason 3 O O
Ergomed, Reason 3 O O
GTH Reason 3 O O
e.V. Reason 3 O O
outside Reason 3 O O
the Reason 3 O O
submitted Reason 3 O O
work. Reason 3 O O
MWP Reason 3 O O
reports Reason 3 O O
research Reason 3 O O
fees Reason 3 O O
from Reason 3 O O
Pfizer Reason 3 O O
and Reason 3 O O
speaker Reason 3 O O
honoraria Reason 3 O O
from Reason 3 O O
Pfizer, Reason 3 O O
Novartis, Reason 3 O O
Thermofisher, Reason 3 O O
GSK, Reason 3 O O
Infectopharm, Reason 3 O O
Bayer, Reason 3 O O
Shionogi, Reason 3 O O
and Reason 3 O O
Chiesi Reason 3 O O
outside Reason 3 O O
the Reason 3 O O
submitted Reason 3 O O
work. Reason 3 O O
Schönborn Reason 3 O O
is Reason 3 O O
supported Reason 3 O O
by Reason 3 O O
the Reason 3 O O
Universitätsmedizin Reason 3 O O
Greifswald Reason 3 O O
within Reason 3 O O
the Reason 3 O O
Gerhard-Domagk-Program. Reason 3 O O
The Reason 3 O O
other Reason 3 O O
authors Reason 3 O O
report Reason 3 O O
no Reason 3 O O
disclosures. Reason 3 O O
Figures Reason 3 O O
Similar Reason 3 O O
articles Reason 3 O O
- Reason 3 O O
[Clinical Reason 3 O O
Characteristics Reason 3 O O
and Reason 3 O O
Pharmacological Reason 3 O O
Management Reason 3 O O
of Reason 3 O O
COVID-19 Reason 3 O O
Vaccine-Induced Reason 3 O O
Immune Reason 3 O O
PMC Reason 3 O O
and Reason 3 O O
hemorrhage Reason 3 O O
after Reason 3 O O
AstraZeneca Reason 3 O O
vaccines Reason 3 O O
followed Reason 3 O O
by Reason 3 O O
35446471 Reason 3 O O
Free Reason 3 O O
PMC Reason 3 O O
article. Reason 3 O O
Review. Reason 3 O O
Cited Reason 3 O O
by Reason 3 O O
- Reason 3 O O
[A Reason 3 O O
Case Reason 3 O O
Report: Reason 3 O O
Long Reason 3 O O
Post-COVID Reason 3 O O
Vaccination Reason 3 O O
Syndrome Reason 3 O O
During Reason 3 O O
the Reason 3 O O
Eleven Reason 3 O O
Months Reason 3 O O
After Reason 3 O O
study: Reason 3 O O
vaccine Reason 3 O O
associated Reason 3 O O
neurological Reason 3 O O
diseases- Reason 3 O O
an Reason 3 O O
experience Reason 3 O O
from Reason 3 O O
an Reason 3 O O
apex Reason 3 O O
neurosciences Reason 3 O O
centre Reason 3 O O
and Reason 3 O O
review Reason 3 O O
Free Reason 3 O O
PMC Reason 3 O O
article. Reason 3 O O
Review. Reason 3 O O
- Reason 3 O O
[A Reason 3 O O
retrospective Reason 3 O O
analysis Reason 3 O O
of Reason 3 O O
clinically Reason 3 O O
confirmed Reason 3 O O
long Reason 3 O O
post-COVID Reason 3 O O
Transl Reason 3 O O
Free Reason 3 O O
PMC Reason 3 O O
article. Reason 3 O O
- Reason 3 O O
[Serious Reason 3 O O
adverse Reason 3 O O
reaction Reason 3 O O
associated Reason 3 O O
with Reason 3 O O
the Reason 3 O O
COVID-19 Reason 3 O O
vaccines Reason 3 O O
of Reason 3 O O
BNT162b2, Reason 3 O O
Ad26.COV2.S, Reason 3 O O
and Reason 3 O O
mRNA-1273: Reason 3 O O
Gaining Reason 3 O O
PMC Reason 3 O O
article. Reason 3 O O
References Reason 3 O O
- Reason 3 O O
- Reason 3 O O
- Reason 3 O O
- Reason 3 O O
Chen Reason 3 O O
R.T., Reason 3 O O
Black Reason 3 O O
S. Reason 3 O O
Updated Reason 3 O O
Proposed Reason 3 O O
Brighton Reason 3 O O
Collaboration Reason 3 O O
Process Reason 3 O O
for Reason 3 O O
Developing Reason 3 O O
a Reason 3 O O
Standard Reason 3 O O
case Reason 3 O O
Definition Reason 3 O O
for Reason 3 O O
Study Reason 3 O O
of Reason 3 O O
New Reason 3 O O
Clinical Reason 3 O O
Syndrome Reason 3 O O
X, Reason 3 O O
as Reason 3 O O
Applied Reason 3 O O
to Reason 3 O O
Thrombosis Reason 3 O O
with Reason 3 O O
Thrombocytopenia Reason 3 O O
Syndrome Reason 3 O O
(TTS) Reason 3 O O
[(accessed Reason 3 O O
on Reason 3 O O
1 Reason 3 O O
August Reason 3 O O
2021)]. Reason 3 O O
Available Reason 3 O O
online: Reason 3 O O
[https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-...](https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf) Reason 3 O O
- Reason 3 O O
Chen Reason 3 O O
R.T., Reason 3 O O
Black Reason 3 O O
S. Reason 3 O O
Updated Reason 3 O O
Proposed Reason 3 O O
Brighton Reason 3 O O
Collaboration Reason 3 O O
Process Reason 3 O O
for O O O O
Developing O O O O
a O O O O
Standard O O O O
case O O O O
Definition O O O O
for O O O O
Study O O O O
of O O O O
New O O O O
Clinical O O O O
Syndrome O O O O
X, O O O O
as O O O O
Applied O O O O
to O O O O
Thrombosis O O O O
with O O O O
Thrombocytopenia O O O O
Syndrome O O O O
(TTS) O O O O
[(accessed O O O O
on O O O O
1 O O O O
August O O O O
2021)]. O O O O
Available O O O O
online: O O O O
- O O O O
2021;384:2124-2130. O O O O
doi: O O O O
10.1056/NEJMoa2104882. O O O O
- O O O O
Publication O O O O
types O O O O
LinkOut O O O O
- O O O O
more O O O O
resources O O O O
Full O O O O
Text O O O O
Sources O O O O
Miscellaneous O O O O
